-
Nov 10, 2020Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021
-
Nov 2, 2020- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th
-
Sep 10, 2020- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration
-
Aug 11, 2020Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020
-
Aug 6, 2020ASCEND results expected to support STS101 NDA filing in Q4 2021
-
Jun 11, 2020Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)
-
Jun 1, 2020More than 1,140 patients randomized and topline results expected in second half 2020
-
May 18, 2020Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations
-
May 12, 2020STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020
-
Mar 10, 2020On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine
-
Nov 12, 2019Completed upsized initial public offering of $90.8 million in gross proceeds